Investment in later stage clinical development is needed to back up recent improvements in the discovery of new antibiotics, and to ensure the use of novel products is managed to maintain their effectiveness
After decades of research – much of it funded by the public - gene therapy is a reality. Now high costs are blocking patient access. Prices should be constrained